178476-11-4

Upstream product

• 136399-05-8 17-bromo-3,6,9,12,15-pentaoxaheptadecan-1-ol 
• 352439-34-0 17-hydroxy-3,6,9,12,15-pentaoxaheptadec-1-yl methanesulfonate 
• 178476-03-4 17-bromo-3,6,9,12,15-pentaoxaheptadecyl 2-acetamido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-β-D-glucopyranoside 
• 178476-04-5 17-bromo-3,6,9,12,15-pentaoxaheptadecyl 2-acetamido-3,6-di-O-benzyl-2-deoxy-β-D-glucopyranoside 
• 100-39-0 benzyl bromide 
• 10378-06-0 2-methyl-(3,4,6-tri-O-acetyl-1,2-dideoxy-α-D-glucopyranoso)[1,2-d]-2-oxazoline 
• 2615-15-8 pentaethylene glycol 
• 1125-88-8 benzaldehyde dimethyl acetal 

Relevant academic research and scientific papers

Synthesis of sialyl Lewis X-polysaccharide conjugates

Sialyl Lewis X (SLe(x)) is well known as a ligand of the cell adhesion molecule E-selectin which is specifically expressed at inflammatory lesion sites. We have synthesized several SLe(x)-polysaccharide conjugates and examined their potential for drug delivery to inflammatory lesions. The AUC (area under the blood concentration-time curve) 0 - 24 h of SLe(x)-CMCht (1), SLe(x)-CMPul (2) and SLe(x)-DSH (3) at the inflammatory lesion was about 60-, 300-, and 30-fold higher than that of the monovalent SLe(x) (7), respectively. Moreover, 1 showed 2-fold higher accumulation in the inflammatory lesion than SLN-CMCht (4), and 2 showed 2.5-fold higher accumulation than SLN-CMPul (5).

Sialyl Lewis X-polysaccharide conjugates: Targeting inflammatory lesions

A novel system for active targeting of inflammattory lesions has been established. A SLe(x)-CMPul conjugate (2) showed accumulation that was 2.5- fold higher in inflammatory lesions in vivo than a SLN-CMPul conjugate (4) and 300-fold higher than monovalent SLe(x) (6).